• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register
Home | baricitinib

baricitinib

Baricitinib: Inhibitor of JAK-STAT Pathway

March 23, 2021

Baricitinib inhibits Janus kinases 1 and 2. These kinases are the first enzymes of the JAK-STAT signaling pathway. This pathway is important for many cell functions. Disorders of JAK-STAT can play a role in cancer and immune disease. For example, baricitinib, a JAK-STAT signaling disrupter, is approved in Europe to treat rheumatoid arthritis.

Progeria and JAK-STAT

Recently, researchers at the Technical University of Munich using a text mining approach had suspicions that a rare premature aging disorder, Hutchinson-Gilford progeria syndrome, is associated with the JAK-STAT pathway. It is known that this syndrome has four main symptoms that mimic normal aging: vascular disease, arthritis, lipodistrophy, and alopecia. In most cases of this disease, a single de novo mutation is responsible for causing the production of progerin, leading to a shortened life span. Unfortunately, sufferers rarely live past the age of thirteen.

The research team decided to run a literature meta-analysis on genes associated with each symptom of progeria. In all, seventeen genes implicated in all four symptoms were found, and of those seventeen, fourteen were part of the JAK-STAT pathway.

Baricitinib Inhibits Janus Kinases

Henceforth, to test the role of the JAK-STAT pathway in progeria experimentally, the team grew cells in culture from progeria patients and also from unaffected controls. The progeric cells expressed abnormal levels of the fourteen identified genes. When the researchers applied baricitinib to the cell culture, the gene expression levels normalized. After one month of baricitinib treatment, progeric cells were less likely to become senescent.

Furthermore, etoposide was also applied to the cell culture, which is known to worsen cell senescence. As anticipated, etoposide treatment disrupted expression of the fourteen genes.

In conclusion, this research shows that the JAK-STAT pathway is likely part of the Hutchinson-Gilford progeria disease mechanism, and baricitinib may have potential as a therapy.

 

Liu C, Arnold R, Henriques G, et al. Inhibition of JAK-STAT signaling with baricitinib reduces inflammation and improves cellular homeostasis in progeria cells. Cells. 2019 Oct 18;8(10):1276. doi: 10.3390/cells810276. PMID: 31635416.

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2025 LKT Laboratories, All Rights Reserved - Products for research use only